Download Image
    
Share
  
Post
BMS mAbs for COVID-19
1 study with 210 patients
Hospital Icon Control
Hospital Icon BMS mAbs Serious Outcome Risk
Significantly lower risk for progression.
COVID-19 BMS mAbs studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -36% Hospitalization -36% Viral clearance 4% RCTs -36% Early -36% FavorsBMS mAbs Favorscontrol
Aug 11
2024
 Focosi, D., Current Topics in Microbiology and Immunology, doi:10.1007/82_2024_268 Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities
Review of monoclonal antibodies for SARS-CoV-2. Author notes that the omicron variant has reset achievements to date.
Aug 8
2024
 Casadevall et al., Clinical Infectious Diseases, doi:10.1093/cid/ciae408 Single monoclonal antibodies should not be used for COVID-19 therapy: a call for antiviral stewardship
Review arguing against use of single monoclonal antibodies for COVID-19 treatment, particularly in immunosuppressed patients, due to the risk of rapidly selecting for resistant viral variants. Authors suggest that while monoclonal antibod..
May 6
2024
 Corada et al., Pathogens & Immunity, doi:10.20411/pai.v9i1.660 Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial
17% lower progression (p=0.03), 20% faster recovery (p=0.19), and 4% improved viral clearance (p=0.45). RCT 211 outpatients with COVID-19 showing no significant difference in time to symptom improvement with subcutaneous BMS-986414 (C135-LS, ogalvibart) and BMS-986413 (C144-LS, crexavibart) monoclonal antibodies compared to placebo. There w..